Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.
Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Biosci Trends. 2020 May 21;14(2):159-160. doi: 10.5582/bst.2020.03058. Epub 2020 Apr 5.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection.
2019 年底至 2020 年爆发的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）大流行对人类健康构成严重威胁。由于目前尚无批准用于预防和治疗的疫苗或药物，因此药物设计和/或已批准药物的临床试验的所有努力都是值得和值得称赞的。使用基于结构的药物选择来鉴定 SARS-CoV-2 蛋白酶抑制剂，大环内酯类（MAC）等旧药物被预测对 COVID-19 有效。最近，大环内酯类的抗病毒作用引起了相当大的关注。最近有报道称，羟氯喹与阿奇霉素联合治疗对 COVID-19 有效。我们认为，单独使用大环内酯类药物或与其他药物联合使用的治疗方法具有广阔的前景，并为抗击这种新兴病毒感染提供了国际策略的可能性。
